P

    Pharming Group NV (PHAR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $11.48
    -0.22 (-1.88%)

    Market Cap: $828.10M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    34%(10/29)
    Avg Surprise
    -109.27%

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$0.20
    Range$0.20 - $0.20
    1 analysts
    EPS RevisionsNo revisions (7d)No revisions (30d)
    EPS Estimate Drift
    90d ago$0.05-75.2%
    60d ago$0.07-64.0%
    30d ago$0.08-59.0%
    7d ago$0.08-59.0%
    Current$0.20
    Revenue Consensus
    $104M
    Range$98M - $108M
    3 analysts
    Dec 31, 2026
    EPS Consensus$0.20
    Range$0.20 - $0.20
    1 analysts
    Revenue Consensus
    $87M
    Range$74M - $99M
    3 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$0.20---
    Sep 26EST
    		-$0.20---
    Jun 26
    		$0.02N/A-90.00%Miss+100.0%
    Mar 26
    		$-0.07$0.01-800.00%Miss-250.0%
    Dec 25
    		$0.07$0.01+498.29%Beat+1300.0%
    Sep 25
    		$0.01N/A+108.00%Beat+165.4%
    Jun 25
    		$0.01$-0.01+200.00%Beat+156.5%
    Mar 25
    		$-0.02$-0.02+0.00%Beat+0.0%
    Dec 24
    		$0.01$0.01-41.18%Miss+112.3%
    Sep 24
    		$-0.02$-0.00-512.00%Miss-253.0%
    Jun 24
    		$-0.02$-0.00-785.00%Miss-277.0%
    Mar 24
    		$-0.02$0.01-300.00%Miss+0.0%
    Dec 23
    		$-0.04$0.00-1002.22%Miss+80.2%
    Sep 23
    		$0.01$-0.01+200.00%Beat+0.0%
    Jun 23
    		$0.01$-0.02+150.00%Beat+0.0%
    Mar 23
    		$-0.02N/A+88.24%Beat-300.0%
    Dec 22
    		$-0.20$-0.21+2.38%Beat-1466.7%
    Sep 22
    		$0.01N/A-97.50%Miss+2100.0%
    Jun 22
    		$0.01$0.01+0.00%Beat-80.9%
    Mar 22
    		$0.01N/A-80.00%Miss-93.6%
    Dec 21
    		$0.01$0.02-25.00%Miss-86.9%
    Sep 21
    		$-0.00N/A-101.21%Miss-103.8%
    Jun 21
    		$0.05$0.10-47.60%Miss+347.9%
    Mar 21
    		$0.16$0.16-1.88%Miss+887.4%
    Dec 20
    		$0.11$0.11+4.00%Beat+845.5%
    Sep 20
    		$0.01N/A-89.00%Miss-35.0%
    Jun 20
    		$0.01N/A-92.20%Miss-32.4%
    Mar 20
    		$0.02N/A-86.75%Miss+39.5%
    Dec 19
    		$0.01N/A-93.95%Miss+8.0%
    Sep 19
    		$0.02N/A-88.72%Miss-22.2%
    Jun 19
    		$0.02N/A-85.58%Miss+106.0%
    Mar 19
    		$0.01$0.00N/ABeat+100.0%
    Dec 18
    		$0.01$0.00N/ABeat+13.1%
    Sep 18
    		$0.03$0.00N/ABeat+130.1%
    Jun 18
    		$0.01$0.00N/ABeat+149.1%
    Mar 18
    		$0.01$0.00N/ABeat+109.6%
    Dec 17
    		$0.01$0.00N/ABeat+177.3%
    Sep 17
    		$-0.09$0.00N/AMiss-374.3%
    Jun 17
    		$-0.02$0.00N/AMiss-
    Mar 17
    		$-0.06$0.00N/AMiss-
    Dec 16
    		$-0.01$0.00N/AMiss-
    Sep 16
    		$-0.02$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio382.67EV/EBITDA20.25x
    Price/FCF25.69xFCF Yield3.89%
    Profitability
    Profit Margin2.54%Operating Margin1.46%
    ROE3.65%ROIC5.39%
    Financial Health
    Debt/Equity0.36xInterest Coverage2.08x
    Current Ratio3.01xQuick Ratio2.31x
    Trading Statistics
    Beta0.06Avg Volume23.71K
    52-Week High$21.3452-Week Low$9.62

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$11.74
    SMA 20$11.57
    SMA 50$12.46
    SMA 200$15.19
    EMA 10$11.70
    EMA 20$11.77
    EMA 50$12.31
    EMA 200$13.75

    MACD

    Line: -0.15Signal: -0.21Hist: 0.06

    ADX

    ADX: 19.8+DI: 21.8-DI: 19.9

    Aroon & PSAR

    Aroon Up52.0
    Aroon Down12.0
    PSAR$13.32

    Bollinger Bands

    Upper Band$12.62
    Lower Band$10.53
    %B Position1809%(Upper)
    Band Width0.46

    RSI (14-Day)

    Neutral
    44.7

    Momentum Oscillators

    Stoch %K21.9
    Stoch %D35.6
    Williams %R-98.4
    ROC (10d)-2.6%
    Momentum-0.31
    CCI (20d)-10.2
    MFI (14d)41.9

    Volatility Measures

    ATR (14d)$0.54(4.7%)
    StdDev (20d)0.52
    Hist Vol49.9%(High)

    Volume Flow

    VWAP$11.54
    OBV-101.4K
    AD Line-162.1K
    CMF (20d)-0.027

    Volume Metrics

    Avg Vol (20d)23.2K
    Vol Ratio0.5x
    VWMA (20d)$11.78

    Pivot Points

    R3$11.98
    R2$11.89
    R1$11.80
    Pivot Point$11.71
    S1$11.62
    S2$11.53
    S3$11.43

    Advanced Oscillators

    TSI-6.92
    Ultimate Osc31.9
    KST-40.80

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$90.21M$72.45M$106.50M$97.29M$93.22M$79.09M$92.70B$74.85M$74.09M$55.59M$81.87M$66.66M
    Cost of Revenue$14.54M$6.64M$21.10M$7.07M$8.97M$8.32M$12.20B$6.82M$7.98M$8.39M$7.16M$8.29M
    Gross Profit$75.67M$65.80M$85.40M$90.22M$84.25M$70.77M$80.50B$68.03M$66.11M$47.20M$74.71M$58.37M
    Operating Expenses$75.78M$71.09M$83.40M$74.47M$75.25M$78.20M$86.10B$64.70M$69.23M$63.51M$74.10M$56.46M
    R&D$32.26M$25.56M$32.10M$23.38M$23.70M$21.14M$22.30B$20.72M$21.60M$18.52M$11.70M$20.75M
    SG&A$14.95M$15.22M$20.00M$16.95M$20.50M$22.49M$51.60B$15.29M$15.62M$15.09M$30.48M$10.89M
    Operating Income$-111,000$-5,288,000$2.00M$15.75M$9.00M$-7,427,000$6.60B$3.33M$-3,121,000$-16,312,000$604,930$1.91M
    Interest Income$1.42M$3.24M$0$485,000$659,000$604,000$1.10M$825,000$920,000$1.78M$1.61M$1.25M
    Interest Expense$2.68M$2.69M$1.40M$7.95M$4,000$5.10M$0$3.00M$1.97M$1.56M$4.54M$1.65M
    Income Before Tax$3.04M$-4,753,000$4.80M$12.76M$7.08M$-11,788,000$6.70B$1.51M$-60,000$-16,624,000$-2,722,169$3.31M
    Income Tax Expense$1.40M$459,000$-500,000$5.21M$2.53M$3.10M$0$2.55M$1.16M$-4,176,000$705,747$-157,000
    Net Income$1.64M$-5,213,000$5.30M$7.55M$4.69M$-14,719,000$2.90B$-1,034,000$-1,218,000$-12,448,000$-2,722,169$3.46M
    EBITDA$8.75M$1.06M$9.41M$23.43M$9.79M$-4,108,000N/A$7.25M$1.91M$-9,147,000$8.17M$4.81M
    EBIT$5.71M$-2,058,000$6.20M$20.70M$7.08M$-6,690,000N/A$4.51M$2.87M$-15,068,000$604,930$1.91M
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about PHAR

    News

    Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Short Interest Up 93.0% in July

    Pharming Group N.V. (NASDAQ:PHAR) saw a significant 93.0% increase in short interest during July, with 19,179 shares shorted as of July 31st. This equates to a days-to-cover ratio of 2.0 days based on average trading volume. The company's stock has faced challenges, trading at $11.72, well below its 52-week high, and missing consensus earnings estimates for the last quarter.

    MarketBeat•8/16/26•
    Somewhat-Bearish

    (PHAR) and the Role of Price-Sensitive Allocations

    This article provides an AI-driven analysis of Pharming Group N.v. (NASDAQ: PHAR), highlighting a near-term strong sentiment potentially challenging mid- and long-term weakness. It outlines specific institutional trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis, to assist investors with different risk profiles. The analysis also points out an exceptional 90.7:1 risk-reward setup targeting a 24.3% gain against a 0.3% risk.

    Stock Traders Daily•8/14/26•
    Somewhat-Bullish

    Pharming announces commercial launch of Joenja (leniolisib)

    Pharming Group N.V. has commercially launched Joenja (leniolisib) in Japan for adult and pediatric patients aged 4 and older with Activated PI3K Delta Syndrome (APDS). This makes Japan the first market where Joenja is available for children aged 4 to 11. OrphanPacific, Inc. is serving as the Marketing Authorization Holder and is responsible for the product's supply and distribution in Japan, following its approval by Japan's Ministry of Health, Labour and Welfare in March.

    GlobeNewswire•8/14/26•
    Bullish

    Pharming Group (PHAR) launches Joenja in Japan for APDS patients aged 4+

    Pharming Group has commercially launched Joenja (leniolisib) in Japan for adult and pediatric patients with Activated PI3K Delta Syndrome (APDS) aged 4 years and older. This makes Japan the first market globally where Joenja is available for children aged 4 to 11. OrphanPacific, Inc. is responsible for the supply and distribution of Joenja in Japan under an agreement with Pharming.

    Stock Titan•8/13/26•
    Bullish

    Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) Given Average Rating of "Hold" by Brokerages

    Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR) has received an average rating of "Hold" from five analysts, with a consensus 12-month price target of $38.67. This comes after the company reported quarterly earnings that missed analyst expectations, with an EPS of $0.02 against an estimated $0.06 and revenue of $90.2 million compared to a $99.52 million consensus. The stock's recent performance shows it trading below its 50-day and 200-day moving averages, with a 52-week range of $9.62 to $21.34.

    MarketBeat•8/13/26•
    Somewhat-Bearish

    Frequently Asked Questions About PHAR

    Does PHAR pay dividends?
    Pharming Group NV (PHAR) does not currently pay a regular dividend.
    What is PHAR's P/E ratio?
    Pharming Group NV has a price-to-earnings (P/E) ratio of 382.67.
    What is PHAR's market cap?
    Pharming Group NV (PHAR) has a market capitalization of $828.10M with a current stock price of $11.48.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In